G1 Therapeutics: Tackling Cancer with Innovative Therapies and Upcoming Financial Update
G1 Therapeutics, Inc., a commercial-stage oncology biopharmaceutical company, will be hosting a webcast and conference call on May 1, 2024, to provide a financial and corporate update for the first quarter of 2024. The event will begin at 8:30 a.m. ET. To register for the event and receive the necessary dial-in information, interested individuals can follow the provided link on the company’s website. It is recommended to join the event 10 minutes prior to the start time. A live and archived webcast will be available on the Events & Presentations page of the company’s website for those who are unable to attend the live event.
G1 Therapeutics is a commercial-stage oncology biopharmaceutical company that aims to develop and deliver next-generation therapies to improve the lives of individuals impacted by cancer. Their first commercial product is COSELA® (trilaciclib), which is used in combination with chemotherapy to treat triple-negative breast cancer in adults who have not responded to previous therapy or whose tumors have progressed after an initial response. Additionally, G1 Therapeutics is evaluating therapies in combination with cytotoxic therapies and/or immunotherapy for conditions with high unmet needs, such as extensive stage small cell lung cancer. The company’s mission is to provide innovative therapeutic solutions for cancer patients. G1 Therapeutics is headquartered in Research Triangle Park, N.C., where they continue their research and development efforts under this mission. To learn more about G1 Therapeutics or their products, visit their website at http://www.g1therapeutics
